Abstract: Biomechanics, which is represented and illustrated as "energy", has enormous effects on biological and medical research. More and more researchers have drowned extensive attentions on this field including ultrasonic and shock wave therapy related application. In the health industry development, biomechanics has a potential role to make great contributions to the human health. In recent years, the convergence of the life science, physical science, and engineering has changed our life totally and this is believed to be the "third revolution of life science". It involves the coming together of different fields of study-particularly engineering, physical science, and life science-through collaboration among research groups and the integration of approaches that were originally viewed as distinct and potentially contradictory. We see convergence as a blueprint for innovation. Advances in information technology, materials, imaging, and quantum physics, coupled with advances in modeling and simulation which have already physical science will bring new idea and challenge to our understanding of health. But as we know, the impact of convergence will not be limited to only health and medicine industry and other scientific areas stand to benefit as well. We and thought leaders in this world all believe that convening study panels and workshops to discuss the intersection of scientific disciplines is not enough for this revolution. We should challenge our historic structure of universities, NSFC, and other department of government. For example, the convergence style research does not fit neatly within the funding categories, nor does it align neatly with the missions of research institutes now we have in our country. We should continue to overcome these problems and develop new investment methods and new models for collaboration. 
Abstract: Prostate cancer is the most commonly diagnosed non-cutaneous solid malignant tumor in the United States. Traditionally, Asian men have been considered low risk for prostate cancer. However, recent research suggests that the prevalence of prostate cancer is increasing in Asian men. This may represent an emerging public health problem with potentially serious consequences for patients and for health care systems. Given a predicted increase in the number of men diagnosed with prostate cancer in Asian countries, there is a clear and present need for optimized protocols for diagnosis and management of this condition in Asian men. Development of such protocols may benefit from novel technologies and lessons learned in Western countries; in this manner patients may receive optimal care and healthcare systems may mitigate the burden of over diagnosis (and subsequent overtreatment) which has complicated management of prostate cancer in the US and other Western nations. Genomic and other molecular testing offers a unique way to stratify oncological risk beyond simple serum, histological, and radiographic markers. These technologies measure genomic or molecular markers that provide novel insights into the biology of prostate tissue and prostate tumors. A variety of molecular biomarkers are in commercial use currently; these include tests designed to: (I) appropriately identify men for prostate biopsy, (II) select men likely to benefit from definitive treatment, and (III) determine which men who should consider adjuvant treatment after initial therapy. Integration of these molecular markers into the care of prostate cancer patients will require changes in how physicians make
